Age-related macular degeneration is the leading cause of late-onset blindness in the industrialized world^[@R9]^. Common *CFH* variants are associated with AMD and meningitis susceptibility. Rare *CFH* mutations cause atypical hemolytic uremic syndrome (aHUS), an episodic illness that causes acute renal failure, and membranoproliferative glomerulonephritis type II (MPGNII), a chronic renal disease^[@R10],[@R11]^. While the possibility that rare *CFH* variants confer AMD risk has been raised^[@R12]^, no advanced AMD risk conferring rare variant has yet been identified.

To identify rare penetrant variants within the *CFH* locus, we phased genotypes for 20 common SNPs spanning the *CFH/CFHR1-3* region and a common *CFHR1-*3 deletion (CFHR1*-3*Δ) in 711 advanced AMD cases and 1041 controls ("Boston-phased" dataset)^[@R13],[@R14]^. Controls included 304 phenotyped controls without evidence of retinal disease and 737 unphenotyped shared controls presumed to not have disease. Almost all these markers are associated with AMD ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We defined 11 common haplotypes (\>0.3% frequency), explaining 97.4% of 3354 chromosomes, and calculated association statistics ([Figure 1A](#F1){ref-type="fig"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Consistent with prior observations^[@R1]--[@R4]^, the most frequent haplotype (**H1**) is present in 59% of case chromosomes but only in 37% of control chromosomes; this haplotype exclusively contains the Y402H^[@R1]--[@R4]^ risk allele (in LD with rs10801555, r^2^=0.99 in 288 genotyped controls). Two haplotypes, **H2** and **H3**, containing a proxy to the rs1410996 *CFH* intronic risk SNP^[@R5],[@R6]^, rs10737680, conferred intermediate risk (OR=0.59 \[0.49--0.71\] relative to **H1**). Excepting **H4**, the remaining haplotypes contained none of the two common risk variants, and in aggregate conferred low risk (OR = 0.30 \[0.26--0.36\] relative to **H1**).

Strikingly, 10 of 11 individuals heterozygote for the rare **H5** haplotype had AMD. The unaffected individual was a 49 year-old unphenotyped male, unlikely to have advanced disease given his age. This proportion of **H5** heterozygote individuals with disease was unexpected since **H5** lacked both the Y402H and rs10737680/rs1410996 risk alleles. We speculated that a rare variant on the **H5** haplotype might explain the data. However, prior to pursuing a sequencing experiment, we considered that the haplotype association was the consequence of chance or stratification. Therefore we asked whether (1) **H5** associated significantly with disease accounting for known AMD-associated common variants; (2) **H5** correlated with earlier age of onset; and (3) the **H5** association could be explained by case-control stratification or recent ancestry.

We assessed the statistical significance of the association of **H5** with advanced AMD by permuting case-control status across all 1,752 subjects. Since we wanted to conservatively assess whether the association was independent of known risk alleles, we were careful to preserve genotypes for four published AMD-associated common markers: Y402H (rs1080155), rs10737680/rs1410996, CFHR1*-3*Δ, and rs800292 (I62V). This permutation fixes case-control allele frequencies, association statistics, and odds ratios at those markers, and also constrains association statistics at the other 17 markers due to underlying linkage disequilibrium in region ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). While common marker association statistics are maintained in these permutations, we rarely observed that ten or more affected heterozygote **H5** individuals (p=0.00081, [Figure 1B](#F1){ref-type="fig"}). Permuting case-control status without preserving marker genotypes or preserving genotypes at only two common markers (Y402H and rs1410996) yield similar results (p=0.00081 and p\<0.00001 respectively). Thus the case-association with this haplotype is beyond what might be expected by chance.

The 10 **H5** heterozygote individuals were diagnosed earlier than the other 701 cases in the Boston-phased data set (median age 62.5 years versus 71 years, p=0.0023 by 1-tailed rank-sum test), further suggesting that **H5** might influence AMD risk.

To assess the possibility that the **H5** association might be the consequence of recent relatedness or population stratification, we selected 79,091 independent SNPs from genome-wide data (**Methods**). We noted first that there was only modest genome-wide stratification (λ~gc~=1.08)^[@R13]^. We projectied genotype data into principal components^[@R14]^ and observed that **H5** heterozygotes do not cluster discretely ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) and that **H5** heterozygote individuals were not skewed along any of the top 20 components (*p*\>0.047, [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). To confirm that **H5** was not the consequence of a recent common ancestry, we estimated the proportion of identity by descent to be \<3% between **H5** heterozygote pairs; at least \~12.5% would be expected for first cousins or more closely related relatives. Taken together, our data suggest that the observed **H5** association is unlikely to be artifactual.

To discover the causal mutation we designed a sequencing experiment. We selected 84 samples representing all 11 haplotypes including homozygote individuals when possible; we included all 10 affected individuals with **H5**. We first applied high-throughput sequencing to a 106.7 kb region containing *CFH* introns, exons, and promotor. We sequenced a subset of 60 individuals (33 cases and 27 controls), representing each of the 11 haplotypes. These samples included 6 **H5** heterozygote individuals. We achieved high coverage with 80% of individuals sequenced at ≥20x for at least 89.3 kb ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Genotype calls from sequencing were 98.9% accurate in 19 separately genotyped SNPs. We identified a total of 623 variants; to avoid false positive calls, we focused our analyses on 356 variants seen at least twice ([Supplementary Table 4, Supplementary Table 5](#SD1){ref-type="supplementary-material"}). We were confident that **H5** specific *CFH* alleles, both coding and non-coding, were likely to be among these since two or more **H5** heterozygotes achieved \>20x coverage in 97.8% of the targetted region. We found only six non-synonymous alleles: (1) rs800292 (I62V); (2) rs1061170 (Y402H); (3) rs1065489 (D936E); (4) rs35274867 (N1050Y); (5) a rare glutamine to histidine variant (Q950H); and (6) a rare exon 22 variant that alters arginine to cysteine, R1210C ([Supplementary Figure 4A](#SD1){ref-type="supplementary-material"}). Of all observed variants, only R1210C variant was seen exclusively in all of the 6 sequenced **H5** heterozygote individuals. To confirm that R1210C was specific for **H5**, we used capillary electrophoresis to sequence exon 22 in all 84 samples ([Supplementary Figure 4B](#SD1){ref-type="supplementary-material"}). Only the ten affected individuals with the **H5** haplotype had the R1210C mutation ([Figure 2](#F2){ref-type="fig"}); we concluded that R1210C was specific for **H5**. We found no other exon 22 variants in any of these 84 individuals.

To confirm the R1210C association and to asses its presence on other haplotypic backgrounds, we genotyped 707 out of the 711 cases and 303 out of 304 examined controls from the Boston-phased data set ([Table 1](#T1){ref-type="table"}). We observed 13 R1210C heterozygote individuals. In addition to the 10 **H5** heterozygote individuals, we identified three more affected individuals with R1210C, two of whom were **H1** homozygote and one that was an **H1/H11** heterozygote. We did not find the R1210C mutation on any controls. This suggested that in addition to being present consistently on the **H5** haplotype, R1210C was also rarely present on **H1**. One possibility is that the R1210C mutation initially occurred on the common **H1** background, and that the **H5** haplotype exists because of a historical recombination with **H6**. These data suggested that R1210C explained the **H5** haplotype association to disease and was associated with advanced AMD (*p*=0.0094 by 1-tailed Fisher's exact test, [Table 1](#T1){ref-type="table"}).

To replicate the R1210C association, we genotyped an independent set of 1,707 cases and 817 controls from Boston and Baltimore sample sets ([Table 1](#T1){ref-type="table"}). We assessed significance with exact statistics since the R1210C heterozygotes were so rare (**Methods**). In this independent case-control replication we observed a statistically significant association (20 in cases vs 1 in controls, one-tailed *p*=0.0052). Combining our case-control replication together with the Boston-phased discovery data set we observed that R1210C heterozygotes were seen in 33/2414 cases (1.4%) compared to 1/1120 controls (\<0.1%), suggesting that this mutation confers a high-degree of risk (one-tailed combined *p*=8.0×10^−5^) and acts as an almost fully penetrant allele. Since Y402H is an influential risk factor at the population level^[@R1]--[@R4]^, we also assessed significance by stratifying for the Y402H genotype (**Methods**). We observed that stratifying on Y402H only increased significance of the R1210C association (one tailed p=9.1×10^−7^). We concluded that R1210C confers risk independently of the common Y402H risk allele.

To further replicate the R1210C association in independent first-degree relatives, we identified 11 siblings of 6 cases with R1210C from the Boston-phased and Boston replication. These siblings were either unambiguously affected with advanced AMD (n=9), or had absolutely no clinical evidence of disease (n=2) ([Table 1](#T1){ref-type="table"}, [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). We observed that 7 of 9 affected individuals were R1210C heterozygotes and 0 of 2 controls were R1210C heterozygotes (p=0.033, one-tailed binomial). In total, aggregating all of the results from our family and case-control data together, we observed a highly significant association (*p*=7.0×10^−6^, p=1.3×10^−7^ stratifying for Y402H, [Table 1](#T1){ref-type="table"}). We estimate that this mutation accounts for \~14% increase in disease prevalence among siblings of affected probands.

Since R1210C apparently has a strong genetic effect, we tested whether the mutation also drives an early age of disease onset. We observed that unrelated individuals with the R1210C mutation had significantly earlier disease onset (median of 65 versus 71 years, *p*=2.3×10^−6^ by rank-sum test, [Figure 3A](#F3){ref-type="fig"}). Of the 55 individuals with an age of onset \<55 years, 5 had the R1210C mutation (8.3%); no individual with onset after 75 years had the R1210C mutation. The retinal phenotype for individual patients with R1210C typically included numerous small, medium, and large drusen ([Figure 3B](#F3){ref-type="fig"}).

Importantly, in our sequencing experiment we found only one rare intronic allele that might potentially contribute to the phenotype; this was a SNP (at 194905360 (HG18)) in 5 of the 6 **H5** heterozygotes ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). However, we consider this allele unlikely to be causal. First, this variant has no evidence of mammalian conservation or regulatory function. Second, applying capillary electrophoresis sequencing to 17 R1210C heterozygote individuals revealed six who individuals lacking the intronic allele, indicating again that the R1210C allele is on multiple haplotypes and that the intronic change is more recent.

The R1210C mutation had been described as an incompletely penetrant allele that causes familial forms of aHUS^[@R15]--[@R19]^, and has also been associated with primary glomerulonephritis^[@R20]^. This allele has been observed worldwide in multiple aHUS families and in 1--4% of individuals in aHUS cohorts^[@R16]^. The R1210C mutation has been shown to compromise C-terminal CFH function; mutant CFH protein has normal cofactor activity but exhibits defective binding to C3d, C3b, heparin, and endothelial cells^[@R7],[@R8],[@R21]^. Moreover, mutant protein product in plasma produces a high-molecular-weight factor H protein, resulting from a covalent interaction with human serum albumin^[@R15]^.

We assessed renal function by estimating the glomerular filtration rate from serum creatinine measurements in 17 unrelated R1210C heterozygotes with advanced AMD. None had evidence of clinically significant renal dysfunction (creatinine\>1.7 mg/dl, eGFR\<30 mL/min), though we noted subclinical renal dysfunction (median eGFR of 62 mL/min). Since AMD patients in general have subclinical renal dysfunction^[@R22]^, we compared renal function to 17 individuals matched on disease severity, age, and gender but without R1210C. We observed no significant difference (one-tailed p=0.54, [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

A previous study proposed that rare *CFH* variants might be compound heterozygous alleles acting in trans with common alleles such as Y402H or I62V^[@R12]^. We found no evidence of this for the R1210C mutation. For the 13 Boston-phased cases with the R1210C (with complete phase information), we observed no excess beyond chance of Y402H risk alleles in trans \[61% (=8/13) versus 59% frequency in all cases\] or I62V risk \[85% (=11/13) versus 87% frequency\] in trans.

Our data suggest that compromised CFH function contributes to AMD pathogenesis and facilitates the transition from association to causality that is ubiquitously necessary to advance studies of complex disorders. We do not exclude possible contributions of neighboring CFH-like loci. Nonetheless, abrogated C-terminal activity of this protein represents potentially the first mechanistic clue about pathogenesis, and could inform attempts to understand the action of other *cis* and *trans* susceptibility alleles. This highlights the value of finding rare alleles with experimentally tractable biological effect in complex traits.

Our data link two clinically unrelated diseases, AMD and aHUS, with common underlying pathology. We note that AMD has common variants in multiple complement pathway genes (*CFI*^[@R23]^, *CFH*^[@R1]--[@R6]^, *CFB*^[@R24]^, and *C3*^[@R4],[@R25]^), and that rare predisposing mutations to aHUS have been observed in these same genes^[@R26]^. Future studies sequencing these genes in large numbers of patients might also reveal rare, high penetrant alleles that could contribute to understanding AMD mechanism.

METHODS {#S1}
=======

Study Sample Descriptions {#S2}
-------------------------

### Case Definitions {#S3}

All individuals, except MIGEN shared controls, were evaluated by a board certified ophthalmologist. For all individuals we either (1) clinically evaluated with visual acuity measurements, dilated slit lamp biomicroscopy, and stereoscopic color fundus photography or (2) reviewed full ophthalmologic medical records. Case patients had either geographic atrophy (advanced dry AMD) or neovascular disease (wet AMD) (Clinical Age-Related Maculopathy Grading System (CARMS) stages 4 and 5)^[@R27]^. Controls were without macular degeneration, and without early or intermediate disease, categorized as stage 1. All Boston controls and most Baltimore samples (\>80%) were ≥60 years old. Individuals with early or intermediate disease were excluded from this study.

### Boston {#S4}

Subjects were recruited through ongoing AMD study protocols^[@R5],[@R28]--[@R31]^; sample ascertainment and genotyping has been previously described^[@R5],[@R23],[@R25]^. All samples were unrelated self-described white individuals of European descent. A subset of these samples were previously genotyped using the Affymetrix SNP 6.0 GeneChip^[@R32]^. We combined those samples passing strict quality-control genome-wide with 100% successful SNP and CNV genotype calls at the *CFH* locus (n=711 cases, 304 controls) with shared control samples from the MIGEN^[@R33]^ study passing the same strict quality control criteria (n=737) to constitute the Boston-phased data set^[@R34]^. Remaining unrelated individuals (n=1,205 cases, 657 controls) comprised the Boston Replication sample.

### Baltimore {#S5}

Unrelated subjects recruited at Johns Hopkins Hospital in Baltimore, MD as previously described^[@R32],[@R35]--[@R37]^, that were self-described white individuals of European descent constituted the Baltimore Replication collection.

### Siblings {#S6}

For individuals with advanced AMD who had the R1210C mutation of interest, we identified siblings within the Boston cohort. We included only extremely discordant siblings with advanced AMD or no evidence of disease to avoid ambiguous diagnoses. Sibling samples are independent of the original Boston-phased and Boston Replication collections.

High throughput sequencing {#S7}
--------------------------

We use long-range PCR tp sequence the whole 107 kb region around *CFH*.

We designed long-range PCR primers to be 28--35 nucleotides long to assure high melting temperature/specificity, without G stretches (4+ Gs), without secondary structure, and without multiple annealing locations genome-wide ([Supplementary Table 7A](#SD1){ref-type="supplementary-material"}). We used the high-fidelity Takara LA DNA polymerase for PCR amplification. Primers for each amplicon was QC tested on control DNA. We selected primer pairs that that successfully generated PCR products and in aggregate covered the whole region of interest. We used the PreCR^™^ (New England Biolabs) repair approach in order to remediate samples that performed poorly during the PCR amplification step.

We cleaned amplicons using Ampure Beads, quantified using Picogreen, and then pooled in equimolar amounts. We constructed libraries with Nextera^™^ (Epicentre Biotechnologies). During the subsequent enrichment step unique index sequences are added for each DNA sample. Ten index libraries were pooled together in a single lane for sequencing. We sequenced pooled index libraries on Illumina IIGX genome analyzer To generate 50 nucleotides paired end read.

We used Burrows-Wheeler Aligner (BWA)^[@R38]^ to align the short reads to the human genome build GRCh37. Duplicate reads were marked and removed using Picard (<http://picard.sourceforge.net>) to avoid recurrent errors in DNA molecules. We performed quality score recalibration and local realignment around indels using the Genome Analysis Tool Kit (GATK)^[@R39]^. We called SNP genotypes with the Unified Genotyper module in GATK based on three metrics a) mapping quality score b) coverage and c) strand bias (see <http://www.broadinstitute.org/software/syzygy/>). Low coverage samples (\<10x depth for \>20kb) and samples with \>15% genotype error with 19 SNPs genotyped on the Affymetrix array were removed. For this study we required that the minimum mapping quality score be at least 10, coverage be at least 20 and the strand bias be at most 0 (where a positive strand bias suggests that variant reads are emerging predominantly from only one of the two strands).

### Confirmation with electrophoresis capillary sequencing {#S8}

We confirmed genotype for sequenced samples with capillary electrophoresis sequencing using the Applied Biosystems^™^ 3730xl platform (see [Supplementary Table 7B](#SD1){ref-type="supplementary-material"} for primers). We analyzed traces using Phred/Phrap/Consed^[@R40],[@R41]^ and mutations were identified with Polyphred^[@R42]^.

Genotyping R1210C {#S9}
-----------------

Once we identified the R1210C mutation, we genotyped it in all available samples -- this includes all samples described above with the exception of MIGEN shared controls. We genotyped Boston samples were genotyped at the Clinical and Translation Research Center Core Lab of Tufts Clinical and Translation Science Institute with a custom TaqMan approach (see [Supplementary Table 8](#SD1){ref-type="supplementary-material"}). We genotyped Baltimore samples at the Duke University Center for Human Disease Modeling using a custom made TaqMan genotyping assay for *CFH* R1210C by Applied Biosystems and with the ABI 7900 Real-Time PCR system.

Statistical Analyses {#S10}
--------------------

### Defining Haplotypes {#S11}

To insure accurate phasing, the individuals in this data set had 0% missing genotype for *CFH* markers. For all markers we constructed haplotypes using the Boston-phased data set across the *CFH* locus with Beagle ^[@R43]^ and PLINK^[@R44]^. We selected haplotypes with frequencies \>0.3%, and calculated case and control frequencies. For each haplotype we calculated odds ratios and 95% confidence intervals relative to the most frequent haplotype.

### Assessing haplotypic association accounting for common SNP associations {#S12}

To quantify the probability that the number of H5 heterozygote individuals might be affected by chance, we permuted the case-control status across all 1,752 individuals in the Boston-phased data set. But, to control for the effects of common associated risk alleles we preserved genotypes at four markers: Y402H (rs1080155), at rs10737680/rs1410996, at CFHR3/1 deletion, and rs800292 (I62V) for each individual. We selected those markers since they have been most commonly suggested as causal alleles in the published literature. All individuals were grouped by genotypes at each of those four markers, and then case-control status within each group was permuted. We conducted 100,000 permutations. For each permutation we calculated the association statistics and odds ratios for each common marker; using all of the permutations we calculated the 95% confidence range for odds ratios and association statistics for each common marker. To assess the significance of our **H5** association we compared the observed number of **H5** individuals with disease to the distribution from permuted results. For comparison, we conducted similar analyses where we permuted case-control status preserving genotyped at no markers at all, and preserving genotypes at only two markers (Y402H (rs1080155) and rs10737680/rs1410996).

### Assessing common ancestry and stratification with genome-wide SNPs {#S13}

To assess relatedness between samples and population stratification, we used the genome-wide SNP data passing stringent quality control from the Affymetrix array on the Boston-phase samples for all 1,752 samples. We required that SNPs met the following criteria (1) Hardy-Weinberg with p\> 0.001, (2) missing genotypes \< 2%, and (3) minor allele frequency \> 5%. We removed SNPs in regions with known association to AMD, the *CFH* locus (chr1, 194--196 MB in HG18 coordinates) and the *ARMS2* locus (chr10, 123--125 MB), along with SNPs in the highly stratified the Major Histocompatability Complex (chr 6, 25--35 MB) and the chromosome 8 inversion region (chr 8, 7--13 MB). Pruning SNPs in linkage disequilibrium (r^2^\<0.2) to insure independence resulted in 79,091 SNPs. To assess whether any of the pairs of H5 individuals had a recent common ancestor, we used these SNPs with Plink^[@R44]^ to estimate identity by descent between pairwise H5 heterozygotes. To assess whether the haplotype association was the consequence of stratification, we applied Eigenstrat to generate principal components for these individuals^[@R14]^. Then we separately plotted cases, controls, and H5 heterozygotes along the top two principal components. To assess whether H5 individuals were skewed along any of the individual top 20 components, we sampled 11 individuals randomly (to match the number of H5 heterozygotes) 10,000 times. For each component we noted the median value for the H5 heterzygotes and compared it to the medians of the randomly sampled individuals. The p-value was the percentage of sampling instances with more extreme than observed median values in either direction.

### Selecting samples for sequencing {#S14}

We aimed to select 90 samples based on available DNA stores for sequencing. We selected only those samples that could be phased into the common identified haplotypes within the CFH locus. Where it was possible, we selected 6 homozygotes for each haplotype randomly from available samples with an equal number cases and controls. When sufficient numbers of homozygotes were not available, up to 16 heterozygotes were selected randomly with an equal number of cases and controls. We selected samples to insure that each common haplotype was represented.

### Statistical test for association of R1210C {#S15}

For single strata case-control sample collections we used a 2×2 Fisher's exact test to calculate a one-tailed *p*-value. Assuming a single strata that there are a total of *N* individuals, of whom *n~case~* are cases and *n~R1210C~* are heterozygotes for the R1210C mutation, we can calculate the one-tailed significance of observing *n~R1210C,cases~* individuals who have the R1210C mutation and also have advanced AMD as follows: $$P_{\mathit{case} - \mathit{control}}\left( n_{R1210C,\mathit{case}} \right) = \sum\limits_{n_{R1210C,\mathit{case}} \leq x \leq n_{R1210C}}{\mathit{hypergeometric}(x,N,n_{\mathit{case}},n_{R1210C})}$$ where *hypergeometric* is the hyper-geometric probability distribution assuming that there are *n~R1210C~* draws from a total of *N* samples, of which x of a total of *n~case~* are drawn. We used this approach to calculate the significance values reported in [Table 1](#T1){ref-type="table"} for Boston-phased, Boston-replication, and Duke-replication not stratified on Y402H genotype.

If multiple strata are present, for example if we are stratifying genotype counts on Y402H genotypes or combining multiple case-control collections together, we expand the above strategy to calculate an exact *p*-value. Assume that we observe a total of *n~R1210C,case~* R1210C heterozygotes who are affected across all strata then, for each strata *j*, we can calculate significance as follows: $$p_{\mathit{stratified},\mathit{case} - \mathit{control}}\left( n_{R1210C,\mathit{case}} \right) = \sum\limits_{\mathit{sum}{({x_{1}\ldots x_{j}})} \geq n_{R1210C,\mathit{case}}}{\mathit{hypergeometric}(x_{1},N_{1},n_{1,\mathit{case}},n_{1,R1210C}) \bullet \ldots \bullet \mathit{hypergeometric}(x_{j},N_{j},n_{j,\mathit{case}},n_{j,R1210C})}$$

Here, for each strata *j* we have separate numbers of total individuals (*N~j~*), separate numbers of individuals who are cases (*n~j,case~*), and individuals with the R1210C genotype (*n~j,R1210C~*). So, we calculate the hyper-geometric probability for each individual strata for all the possible counts that would result in an equal or greater than *n~R1210C,case~* total number of heterozygtes associated with advanced AMD, and total these probabilities together to obtain a p-value.

For first-degree siblings we calculated statistical significance using the binomial distribution. Given that siblings were selected from affected probands that had the R1210C mutation, the probability that each additional relative would have the mutation is 0.5. We assign each sibling a score, *s~i~* which is 1 if the sibling has both advanced AMD and R1210C or if the sibling neither advanced AMD or R1210C and 0 if the sibling has advanced AMD without R1210C or R1210C without advanced AMD. We obtain an aggregate score by summing over all independent siblings: $$s_{\mathit{siblings}} = \sum\limits_{i}s_{i}$$

Under the null hypothesis, the aggregate score should be distributed according to a binomial distribution. So if there are a total of *n~siblings~* we can calculate *p~sibling~*, the one-tailed significance: $$p_{\mathit{siblings}}\left( s_{\mathit{siblings}} \right) = \sum\limits_{x \geq s_{\mathit{siblings}}}{\mathit{binomial}\left( {x,n_{\mathit{siblings}},0.5} \right)}$$ where the function *binomial* represents the binomial distribution for *x* successful draws out of *n~siblings~* each with a 0.5 probability.

In order to calculate an aggregate meta-analysis we define a score, *s~aggregate~* which is the total of *n~R1210C,case~* across all strata and *s*. We can calculate the probability of obtaining the score *s* or a more significant score to determine the exact one-tailed p-value: $$p_{\mathit{meta}}\left( s_{\mathit{aggregate}} \right) = \sum\limits_{s_{\mathit{aggregate}} \leq \mathit{sum}(x_{i}\ldots x_{j}) + y}{\mathit{binomial}\left( {y,n_{\mathit{siblings}},0.5} \right)} \bullet \prod\limits_{j}{\mathit{hypergeometric}(x_{j},N_{j},n_{j,\mathit{case}},n_{j,R1210C})}$$

### Statistical analysis of age of onset {#S16}

For 1910 out of 1912 unrelated individuals affected with advanced AMD from Boston-phased and Boston-replication samples we had information on age of disease onset. Age of onset is defined as the age at which the individual was first diagnosed with AMD, which might predate the age at which patients fulfilled the case-definition of advanced AMD. We used a non-parametric Wilcoxon rank-sum test to test if affected individuals with the R1210C mutation had earlier age of onset than those without this mutation.

### Assessing renal function {#S17}

For 17 unrelated individuals from Boston-phased with advanced AMD and the R1210C mutation, we determined the creatinine concentration using the DetectX Serum Creatinine Detection Kit (Cat\# KB02-H1, Arbor Assays, Ann Arbor, Michigan) on stored serum. We calculated eGFR using the MDRD formula^[@R45]^. We then selected 17 other individuals from Boston-phased, also with advanced AMD, but without the R1210C mutation. We matched individuals for gender, age at the time of serum collection, and stage of AMD for each eye at the time of serum collection. We measured serum creatinine on stored serum for these individuals, and calculated eGFR. We compared eGFR of R1210C individuals to matched controls with a paired non-parametric Wilcoxan signed rank test.
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###### 

**A. Phasing 21 markers in the *CFH/CFHR1/CFHR3* region**. Here we present association statistics of 11 haplotypes with frequencies \>0.3%, resulting from phasing 20 SNP markers and a *CFHR1-3* common copy number polymorphism. We specifically note the *CFH* rs800292 (I62V) SNP; the *CFH* Y402H proxy, rs10801555; *CFH* rs1410996 proxy, rs10737680; and the *CFHR1-3* deletion. For most SNPs we list the nucleotide, for the *CFHR1-3* deletion the empty circle (◎) indicates the region is deleted while the filled circle (◉) indicates the region is not deleted. To the right of each haplotype, we note the observed frequency in cases and controls. To the far right of each haplotype we note the relative ratio of the odds of disease for each haplotye relative to *H1*. For the H5 haplotype we note that it has a significantly greater allelic odds ratio than H1. The contrast is more striking when compared to the aggregate odds ratio of haplotypes H4-H11 (red dot to the left of the H5 OR). **B. Case-control permutations preserving genotype at four common AMD associated markers.** Here we present a histogram of the number of **H5** heterozygote individuals that are cases for each of the 100,000 permutations. We place an arrow at 10, the observed number of **H5** heterozygote individuals that are cases in the actual data (*p*=0.00081).
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![Sequencing the H5 haplotype identifies an R1210C mutation\
We applied capillary electrophoresis sequencing to 84 individuals representing the common *CFH* haplotypes depicted in [Figure 1](#F1){ref-type="fig"}. Each circle represents an individual. The position on the grid indicates the two haplotypes for the individual at the *CFH* locus; individuals along the diagonal are homozygous for a haplotype. Individuals that do not have the R1210C mutation are depicted with an empty circle (◎). Individuals that are heterozygous for the R1210C mutation are indicated with a filled red circle (◉). All 10 individuals with the R1210C mutation are heterozygous for the **H5** haplotype, strongly suggesting that the mutation is on that haplotype, and accounts for the increased risk associated with that haplotype.](nihms335193f2){#F2}

###### The phenotype of the R1210C mutation

**A.** Here we plot a histogram of the age of onset for 23 individuals with the R1210C mutation and also for 1,887 individuals without the R1210C mutation from Boston-phased and Boston-replication with available data. Age of onset is defined as the age when the patient starts showing signs of AMD. While the median age of diagnosis for affected individuals with the R1210C mutation is six years less than those without (65 versus 71 years), the mean age is 8.6 years less (61.9 versus 70.5 years). **B.** Fundus photograph of the right eye of a subject with the R1210C mutation showing central geographic atrophy (advanced dry age-related macular degeneration) surrounded by numerous large and very large drusen in the posterior pole and along the vascular arcades. Drusen were present nasal and temporal to the macula and in all four quadrants out to the mid-peripheral retina.
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###### Genotyping results

This table presents the genotyping results of individuals from three case-control collections, and also from siblings of individuals in the Boston collections with the R1210C mutation. The first row describes the results of individuals from the Boston-phased data set, used to generate the haplotypes illustrated in [Figure 1](#F1){ref-type="fig"}. The next two rows describe data from two replication collections. The third row presents aggregate statistics of the replication collections. The fourth row presents aggregate statistics from all of the case-control data sets, including both the replication data and the Boston-phased data set. The fifth row presents the results of genotyping siblings of affected individuals with the R1210C mutation. The final row presents statistical significance data of all of the above data sets. For each data set, we present counts of affected and unaffected individuals with and without the R1210C mutation. We also list one-tailed *p*-values for each row, with and without stratifying on Y402H genotype.

                                        R1210C Heterozygotes   R1210 Homozygotes   One-tailed p-value                   
  ------------------------------------- ---------------------- ------------------- -------------------- ----- --------- ---------
  1\. Boston-Phased                     13                     0                   694                  303   0.0094    0.0030
  2\. Boston Replication                10                     1                   1195                 656   0.058     0.0086
  3\. Baltimore Replication             10                     0                   492                  160   0.062     0.016
  All Replication (2+3)                                                                                       0.0052    0.00021
  All Case-Control (1+2+3)              8.0E-05                9.1E-07                                                  
  4\. First Degree Relatives (Boston)   7                      0                   2                    2     0.033     
  Meta-Analysis (1+2+3+4)                                                                                     7.0E-06   1.3E-07
